# Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia

> **NCT03473119** · — · UNKNOWN · sponsor: **Taipei Medical University WanFang Hospital** · enrollment: 600 (estimated)

## Conditions studied

- Pneumonia
- Chronic Obstructive Pulmonary Disease
- Asthma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03473119
- **Lead sponsor:** Taipei Medical University WanFang Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-03-19
- **Primary completion:** 2021-03-19
- **Final completion:** 2021-03-19
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2019-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03473119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03473119, "Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03473119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*